Professor of Medicine
Office Phone: 202-741-2238
- M.B.B.S, Madras Medical College,Madras University,India, 1986
Muralidharan Jagadeesan, MBBS, MD, FACP, FASN is the Section Chief of Transplant Medicine in the Division of Kidney Diseases and Hypertension at the George Washington University (GW) School of Medicine and Health Sciences and the GW Medical Faculty Associates. He also is the Medical Director of the Renal Transplant Program at the George Washington University Hospital.
Dr. Jagadeesan received his MBBS from the Madras Medical College, University of Madras, India. He completed a Residency in Internal Medicine at the State University of New York, and subsequently fellowships in General Nephrology and Transplant Nephrology at the University of Toronto, where he went on to complete his post-doctoral research training under Leendert C Paul MD. He is an invited Fellow of the American College of Physicians and a Fellow of the American Society of Nephrology.
After completing his fellowship, Dr. Jagadeesan joined the Faculty at the Division of Nephrology at the Medical College of Georgia, where his efforts were instrumental in the development and expansion of the transplant program. He also the founding Program Director of a very highly successful Transplant Fellowship Program. He started the Kidney Transplant Program at the George Washington University, and has led it since, its inception as it’s Medical Director. The program under his leadership, has expanded in a short span of five years to a highly successful program, providing outstanding clinical care, with excellent clinical outcomes. He established the “transplant medicine inpatient service at the GW Hospital” and implemented “protocol biopsies” to practice precision transplant medicine.
As a clinical researcher, Dr. Jagadeesan has been involved in numerous landmark clinical studies, including the BENEFIT and OPTIMA trials in Kidney Transplantation, and the SPRINT study in Hypertension, as well as groundbreaking Translational Research in Precision Medicine. He is currently involved in several pivotal studies including the Canadian-Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK), and APOL1 Long term kidney transplantation outcome Network (APOLLO). He helped organize the American Association of Kidney Patients (AAKP) conference last year at George Washington University.
Dr. Jagadeesan is a well-recognized leader in Transplant Nephrology and with numerous publications to his credit. He has been a visiting professor at several institutions and has mentored and trained several generations of nephrologists and transplant physicians, many of whom have gone on to successful academic careers. He is a remarkable clinician, committed educator and a passionate patient advocate, who has been committed to improving access to transplantation and equity in patient care.
Internal Medicine, Woodhull Medical Center (SUNY-Brooklyn) 1990 - 1993
Nephrology, University of Toronto, 1993-1995
Transplant nephrology, University of Toronto, 1996-1997
- Transplant Nephrology
- General Nephrology
- Pre-transplant Evaluations
- Post-transplant Care
- Novel immunosuppression
- Across the blood group transplantation
- Transplantation in HIV patients
- Post-transplant Infections
- Post-transplant malignancies
- Provided Care in an Indigent Care Clinic in Augusta GA for last 5 years
- Education of patients with Kidney Disease through meetings and presentations in the DC area
- Renal Diseases and Hypertension
View publications by this faculty member.
Raj Dominic, Jagadeesan Muralidharan, Aminrazavi et al. . Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney disease among Patients with Chronic Kidney Disease – CJASN, 2015 (In press)
Horuzko, Kapoor, Jagadeesan, Mulloy et al. HLA dimers in prolongation of Kidney Allograft Survival. Journal of Immunology Research, 2014
Gaber et al and the Sirolimus Study Group@ Transplantation. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. 2008 Nov 15;86(9):1187-95.
Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Coadministration of tacrolimus with anti-acid drugs. Transplantation. 2003 Aug 27;76(4):665-6.
Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Two-Year economic evaluation of clinical pharmacy services in renal transplant clinic patients. American Transplant Congress Transplant 2002, April 26 – May 1, 2002.
Chisholm MA, Mulloy LL, Jagadeesan M, Martin BC, DiPiro JT. Effect of clinical pharmacy services on the blood pressure of African-American renal transplant patients. Ethnicity & Disease. 12(3):392-397, July 2002.
Paul LC, Muralidharan J, Valentin JF, Muzzafar SA. Antibodies against mesangial cells and their secretory products. American Journal of Pathology 152:1209-1223, 1998.
Paul LC, Muralidharan J, Bennediktsson H. Immunological and hemodynamic mechanisms in chronic allograft rejection. Transplantation Immunology 4(1):39-42, 1996.
Industry Relationships and Collaborations
This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.